The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vascular endothelial growth factor (VEGF)–targeting therapies for endocrine-refractory or -resistant metastatic breast cancer (MBC): Preliminary results of a systematic review and meta-analysis.
A. D. Wagner
No relevant relationships to disclose
C. Thomssen
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
J. Haerting
No relevant relationships to disclose
S. Unverzagt
No relevant relationships to disclose